Latest News and Press Releases
Want to stay updated on the latest news?
-
BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
-
BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
-
- Bolstered Board of Directors and Scientific Advisory Board with key appointments - - On track for anticipated 2022 milestones including submission of IND and/or CTA for DB-OTO and interim...
-
BOSTON, June 02, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
-
BOSTON, May 24, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
-
BOSTON, May 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
-
– Established cGMP manufacturing and development agreement with Catalent for otoferlin dual-vector gene therapy, DB-OTO – – Successfully completed the second tranche of an oversubscribed Series D...
-
Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy 24th Annual Meeting
BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
-
BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
-
-Successfully completed an oversubscribed Series D financing and upsized Initial Public Offering raising approximately $220.1M in gross proceeds- -Established development and manufacturing agreement...